2024
Association Between Immunoparesis and Treatment Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis
Siwakoti A, Khadka S, Grimshaw A, Giri S. Association Between Immunoparesis and Treatment Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis. Clinical Lymphoma Myeloma & Leukemia 2024, 24: e870-e877. PMID: 39179448, DOI: 10.1016/j.clml.2024.07.008.Peer-Reviewed Original ResearchNewly diagnosed multiple myelomaProgression free survivalImpact of immunoparesisVisual examination of funnel plotsAssociated with worse OSOverall survivalMultiple myelomaFree survivalPrognostic impactPre-published protocolFunnel plotMeta-analysisHazard ratioTreatment outcomes of patientsPublication biasOutcomes of patientsContour-enhanced funnel plotsImmune system perturbationsInfection rateCause of mortalityInfection riskMicro AbstractClinical outcomesImmunoparesisPolyclonal immunoglobulins
2023
The Impact Of Immunoparesis On Outcomes Of Patients With Newly Diagnosed Multiple Myeloma: A Systematic Review
Siwakoti A, Khadka S, Grimshaw A, Giri S. The Impact Of Immunoparesis On Outcomes Of Patients With Newly Diagnosed Multiple Myeloma: A Systematic Review. Journal Of Allergy And Clinical Immunology 2023, 151: ab78. DOI: 10.1016/j.jaci.2022.12.248.Peer-Reviewed Original Research
2020
Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors
Giri S, Grimshaw A, Bal S, Godby K, Kharel P, Djulbegovic B, Dimopoulos MA, Facon T, Usmani SZ, Mateos MV, Costa LJ. Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors. JAMA Oncology 2020, 6: 1759-1765. PMID: 32970151, PMCID: PMC7516804, DOI: 10.1001/jamaoncol.2020.4338.Peer-Reviewed Original ResearchConceptsProgression-free survivalHigh-risk MMBackbone regimensRefractory MMHazard ratioMultiple myelomaClinical trialsSystematic reviewDerSimonian-Laird random-effects modelPhase 3 trialImproved response ratesPreferred Reporting ItemsRandom-effects modelCochrane riskSame regimenCytogenetic riskCochrane LibraryMeeting libraryI2 statisticImproved outcomesMAIN OUTCOMEThird investigatorCochran's QPatientsReporting ItemsEfficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis
Giri S, Aryal MR, Yu H, Grimshaw A, Pathak R, Huntington SP, Dhakal B. Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis. Journal Of Geriatric Oncology 2020, 11: 1285-1292. PMID: 32513568, PMCID: PMC8721742, DOI: 10.1016/j.jgo.2020.05.013.Peer-Reviewed Original ResearchConceptsTransplant-ineligible patientsMultiple myelomaTreatment optionsPhase II/IIICumulative ranking (SUCRA) probabilitiesFirst-line treatmentHematopoietic cell transplantationTerms of efficacyRandom-effects modelEfficacious regimensFrailty biomarkersFrontline regimensThalidomide maintenanceEffective regimensGeriatric assessmentLine treatmentTreatment regimensCell transplantationMeeting libraryIndividual patientsToxicity profileRegimensPatientsSystematic reviewRanking probabilityEfficacy of daratumumab in the treatment of multiple myeloma with high-risk cytogenetics: Meta-analysis of randomized phase III trials.
Giri S, Grimshaw A, Bal S, Godby K, Kharel P, Djulbegovic B, Usmani S, Facon T, Moreau P, Dimopoulos M, Mateos M, Costa L. Efficacy of daratumumab in the treatment of multiple myeloma with high-risk cytogenetics: Meta-analysis of randomized phase III trials. Journal Of Clinical Oncology 2020, 38: 8540-8540. DOI: 10.1200/jco.2020.38.15_suppl.8540.Peer-Reviewed Original ResearchHigh-risk cytogeneticsProgression-free survivalPhase III trialsMultiple myelomaR settingIII trialsMature overall survival dataDerSimonian-Laird random-effects modelPhase III randomized trialsRandomized phase III trialFirst-line settingOverall survival dataImproved response ratesRandom-effects modelLog hazard ratioBackbone regimenBackbone regimensHRC patientsRefractory settingPrimary endpointSame regimenFree survivalCytogenetic riskMM patientsRandomized trials
2019
Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled Trials
Giri S, Aryal M, Yu H, Grimshaw A, Pathak R, Huntington S, Dhakal B. Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled Trials. Blood 2019, 134: 2188. DOI: 10.1182/blood-2019-130389.Peer-Reviewed Original ResearchProgression-free survivalOverall response rateHematopoietic cell transplantFront-line treatmentAdverse eventsOverall survivalMM patientsMultiple myelomaFrontline regimensClinical trialsAdvisory CommitteeCommon grade 3Cumulative ranking (SUCRA) probabilitiesFront-line regimensHigher adverse eventsPrimary efficacy outcomeTransplant-ineligible patientsPhase III RCTsNetwork Meta-AnalysisBias assessment toolRisk of biasEvaluation of efficacyIndividual patient needsEfficacious regimenEfficacious regimens